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Abstract
Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein 
thrombosis, is a condition characterized by abnormal blood clot formation in the pulmo-
nary arteries and the deep venous vasculature. It is often serious and sometimes even 
fatal if not promptly and appropriately treated. Moreover, the later consequences of VTE 
may result in reduced quality of life. The treatment of VTE depends on various factors, 
including the type, cause, and patient comorbidities. Furthermore, bleeding may occur 
as a side effect of VTE treatment. Thus, it is necessary to carefully weigh the benefits versus 
the risks of VTE treatment and to actively monitor patients undergoing treatment. Asian 
populations are known to have lower VTE incidences than Western populations, but re-
cent studies have shown an increase in the incidence of VTE in Asia. A variety of treatment 
options are currently available owing to the introduction of direct oral anticoagulants. 
The current VTE treatment recommendation is based on evidence from previous studies, 
but it should be applied with careful consideration of the racial, genetic, and social charac-
teristics in the Korean population.
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Fig. 1.  Overview of anticoagulant therapy for venous thromboembolism. a)Doses can be modified according to organ function, body weight, or 
concomitant medications. 
Abbreviations: INR, international normalized ratio; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin. 
INTRODUCTION
Venous thromboembolism (VTE) includes pulmonary em-
bolism (PE), which is potentially fatal and causes chronic 
thromboembolic pulmonary hypertension, and deep vein 
thrombosis (DVT), which causes leg swelling and post-
thrombotic syndrome. In addition, VTE may develop in a 
splanchnic vein and in other atypical locations. Currently, 
cancer-associated thrombosis (CAT) is highlighted due to 
the increased prevalence of cancer. Although the incidence 
of VTE in Asian populations, including that of Korea, is 
lower than that in Western populations [1], the age- and 
sex-standardized annual incidence rate (ASR) of VTE per 
100,000 individuals in the Korean population has increased 
steadily starting in 2004 [2], and this increase has been main-
tained, leading to an ASR of 29.2% in 2013 [3].
Among cardiovascular diseases, PE is the third most com-
mon cause of death, after heart attack and stroke [4]. The 
fatality rate is approximately 6% after DVT and approx-
imately 12% after PE [5].
Vitamin K antagonists (VKA; warfarin) and low-molec-
ular-weight heparin (LMWH) have been used for the treat-
ment of VTE. However, direct oral anticoagulant (DOAC) 
therapies have also been developed; DOACs have been com-
monly used for the treatment of VTE since the mid-2000s 
because they do not require regular hematologic monitoring, 
and fixed-dose oral intake is convenient. In Korea, dabigatran 
was first covered by the National Health Insurance System 
in May 2015, and rivaroxaban, apixaban, and edoxaban were 
subsequently approved for VTE treatment. Overall, VKA 
has been rapidly replaced by DOACs in the market [3]. 
Therefore, the development of Korean guidelines for VTE 
treatment is needed for Korean clinicians, although the re-
sults of clinical trials for Korean patients with VTE [6] are 
still scarce.
The members of the Thrombosis and Hemostasis Working 
Party under the Korean Society of Hematology decided to 
develop Korean recommendations for VTE treatment. All 
members are clinical or laboratory hematologists, and most 
are affiliated with tertiary teaching hospitals. The group 
divided the specific topics pertaining to VTE treatment 
among the members; subsequently, the members wrote the 
manuscript, referencing recent guidelines, meta-analyses, 
and the results of pivotal clinical trials while reflecting on 
domestic circumstances in Korea. After completion of the 
manuscript draft, independent members in the field of 
thrombosis and hemostasis reviewed the primary manuscript. 
All members reviewed the completed manuscript several 
times.
This recommendation is not a manual for VTE treatment. 
Physicians must consider each clinical situation and the pa-
tient’s condition or status when making decisions. The diag-
nosis or prophylaxis of VTE is beyond the scope of our 
recommendation. This recommendation may aid in clinical 
decision-making for Korean patients with VTE.
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Table 1. Use of anticoagulants for the treatment of venous 
thromboembolism in patients with renal insufficiency.
Anticoagulant Recommendationa)
Unfractionated heparin CrCl ≥30 mL/min: no adjustment
CrCl ＜30 mL/min: no adjustment, use 
with caution
LMWH CrCl ≥30–80 mL/min: no adjustment, 
use with caution
CrCl ＜30 mL/min: enoxaparin - 1 
mg/kg subcutaneously once a day, use 
with caution, anti-Xa monitoring is 
recommended if applicable; 
dalteparin - dose adjustment 
according to anti-Xa activity, use with 
caution 
Warfarin No adjustment recommended
Edoxaban CrCl ≥50 mL/min: no adjustment
CrCl 15–49 mL/min: 30 mg once daily
CrCl ＜15 mL/min: not recommended
Dabigatran CrCl ≥50 mL/min: no adjustment
CrCl 30–49 mL/min: 110 mg twice daily
CrCl ＜30 mL/min: not recommended
Rivaroxaban/Apixaban CrCl ≥30 mL/min: no adjustment
CrCl 15–29 mL/min: no adjustment, use 
with caution
CrCl ＜15 mL/min: not recommended
a)Detailed recommendations may differ slightly according to 
guidelines and in the context of clinical trials. The list above is based 
on the approval package of each drug from the Korean Food and 
Drug Safety (KFDS) for the treatment of venous thromboembolism.
Abbreviations: CrCl, creatinine clearance; LMWH, low-molecular- 
weight heparin.
APPROPRIATE SELECTION OF TREATMENT 
MODALITIES AND ANTICOAGULANTS FOR VENOUS 
THROMBOEMBOLISM 
General principle of anticoagulation
Medical anticoagulation consists of 3 periods: acute (the 
first 5–21 days), long-term (3–6 mo), and extended period 
(thereafter; Fig. 1). In the acute period, anticoagulants are 
loaded via parenteral heparin lead-in or a higher dose of 
oral anticoagulants is administered. For long-term treatment, 
the general anticoagulant treatment period for postoperative 
VTE is 3 months because of the low risk of recurrence, 
but is prolonged to 6 months for unprovoked VTE. Extended 
treatment can be considered in some cases with a high risk 
of VTE recurrence.
For the treatment of VTE, heparin and VKA have been 
used widely for a long time, although DOACs are quickly 
replacing them because of their convenience of use. 
However, in certain situations or for patients who have al-
ready been using older anticoagulants for a long time, heparin 
and VKA can continue to be used [7]. LMWH is also fre-
quently used, especially in cases of CAT. Compared to un-
fractionated heparin (UFH), it is more likely to show a pre-
dictable dose-response relationship. It has a longer half-life, 
allowing it to be administered subcutaneously once a day 
or twice a day, with a lower risk of heparin-induced thrombo-
cytopenia and osteoporosis. Because LMWH is excreted 
mainly by the kidney, it should not be used in patients 
with severe renal impairment. Conversely, UFH has a shorter 
half-life and can thus be useful in patients who require 
an immediate anticoagulant effect to support rapid 
conversion. VKA is absorbed in the gastrointestinal tract 
and metabolized in the liver. It exhibits moderate anti-
coagulant effects by inhibiting vitamin K between 48 and 
72 h after the start of administration. Because protein C 
and protein S, which are considered natural anticoagulants, 
may also decrease during the priming of VKA, the risk of 
thrombosis and skin necrosis increases in the first 2 or 3 
days of VKA use. Therefore, during this period, VKA should 
be administered with heparin. The effect of VKA is affected 
by the patient’s liver function, concurrent medication, and 
food intake; therefore, careful monitoring is required.
Dabigatran directly inhibits factor IIa, while rivaroxaban, 
apixaban, and edoxaban inhibit factor Xa. Several large-scale 
phase 3 studies have compared DOAC therapies with VKA, 
confirming that DOACs are not inferior in terms of antith-
rombotic efficacy and bleeding [8-11]. Thus, DOACs have 
been used instead of VKA for the treatment of VTE. The 
major drug absorption sites of rivaroxaban, dabigatran, and 
edoxaban are the stomach and the proximal small intestine. 
Therefore, in patients with previous total gastrectomy, these 
drugs should be taken with caution because they may not 
be absorbed efficiently. Unlike other DOACs, apixaban is 
mostly absorbed in the distal small intestine and ascending 
colon and can be safely used in patients who have undergone 
gastrectomy; however, it should be avoided in patients who 
have previously undergone resection of the ascending colon 
[12]. Dabigatran is produced as a capsule formulation. Thus, 
when the capsule of dabigatran is opened and the contents 
are taken alone, its bioavailability rises rapidly. Opening, 
crushing, or chewing dabigatran capsules is prohibited.
For the use of DOACs in cases of CAT, see the section 
‘Treatment of cancer-associated venous thromboembolism’.
Anticoagulation in special situations
Anticoagulation in renal insufficiency: Because the main ex-
cretion site of DOACs is the kidney, the anticoagulant effect 
of DOACs increases in the presence of renal insufficiency, 
and the likelihood of bleeding complications also increases. 
Since patients with renal insufficiency were not included 
in the clinical trials of DOACs (for example, a creatinine 
clearance of ＜30 mL/min was an exclusion criterion for 
an edoxaban trial [13]), attention should be given to the 
use of DOACs in cases of renal insufficiency. Conversely, 
LMWH, such as dalteparin, can be used safely in patients 
with moderate renal impairment. The use of anticoagulants 
according to renal function is summarized in Table 1.
Anticoagulation in thrombocytopenia: In cases of CAT with 
thrombocytopenia, mostly in hematologic malignancies, 
LMWH is the preferred anticoagulant because of its shorter 
half-life and better safety profile than VKA. DOACs may 
also be considered for these patients. However, the pivotal 
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trials of DOACs for CAT excluded patients with a platelet 
count ＜50,000×109/L [13], or even ＜75,000×109/L [14]; thus, 
there is insufficient data on whether DOACs can replace 
LMWH in the setting of CAT combined with significant 
thrombocytopenia. Therefore, the use of DOACs in patients 
with thrombocytopenia requires caution, and decisions 
should be individualized until more robust evidence is 
gathered.
Thrombolytic therapy and inferior vena cava filter insertion: 
Sometimes, thrombolytic therapy can be administered either 
through systemic infusion via a vein or directly to the throm-
bus by inserting a catheter. However, as the risk of bleeding 
increases, this method should be considered only in cases 
of hemodynamically unstable PE. An inferior vena cava (IVC) 
filter can be considered in patients with DVT to prevent 
PE when anticoagulation is contraindicated (e.g., bleeding), 
but the general use of IVC filters or permanent indwelling 
hardware should be avoided [15].
TREATMENT OF VENOUS THROMBOEMBOLISM
Treatment of deep vein thrombosis
Treatment of proximal deep vein thrombosis:  Proximal lower 
extremity DVT occurs when a thrombus is located in the 
popliteal, femoral, or iliac veins. Clinical symptoms vary 
according to the anatomy, extent, and degree of occlusion, 
and range from asymptomatic to extensive edema and 
gangrene. Anticoagulant therapy is indicated for all patients 
with proximal DVT [16]. In the case of active hemorrhage, 
lower platelet counts (＜50,000×109/L) or prior intracerebral 
hemorrhage, an IVC filter is preferable. Recommendations 
for the treatment of provoked proximal DVT includes 3 
months of anticoagulant therapy [16]. In patients with an 
unprovoked proximal DVT, extended anticoagulant therapy 
(at least 3 months and potentially indefinite) is preferred, 
while in patients with high bleeding risk, 3 months of anti-
coagulant therapy is recommended [16]. Therapeutic options 
for proximal DVT include VKA, LMWH or DOACs. A se-
lection among these agents is usually made based on clinician 
experience, as well as the risks of bleeding, patient comorbid-
ities, preferences, cost, and convenience. Thrombolytic ther-
apy is not recommended, except for patients with massive 
iliofemoral or femoral DVT with a high risk of limb gangrene 
[16].
Treatment of isolated distal deep vein thrombosis: Isolated 
distal DVT is diagnosed when a thrombus forms below the 
popliteal vein without extension to the proximal veins. The 
decision of whether to treat isolated DVT is controversial, 
as the 3-month recurrent VTE risks of isolated distal DVT 
between the untreated and treated groups were discordant 
between studies [17-20], although the absolute risk of VTE 
recurrence is reportedly lower than that of proximal DVT 
or PE. In addition, in contrast to proximal DVT and PE, 
a guideline for the management of isolated DVT is not sup-
ported by high-level evidence. A meta-analysis of 24 studies 
involving 4,072 patients reported that anticoagulation re-
duced VTE recurrence rate compared to no anticoagulant 
treatment [odds ratio (OR), 0.50; 95% confidence interval 
(CI), 0.31–0.79], without increasing the rate of major bleeding 
(OR, 0.64; 95% CI, 0.15–2.73) [21]. In contrast, based on 
the evidence of a randomized placebo-controlled prospective 
trial [22], asymptomatic patients without high-risk features 
of VTE recurrence or extension (immobilization, active can-
cer, unprovoked VTE) and with a high risk of bleeding, 
may undergo surveillance with serial screening for DVT 
of the lower leg without anticoagulation. However, if patients 
are acutely symptomatic, have high-risk features for re-
currence and extension, and are without bleeding risk, anti-
coagulation is recommended [16]. Aspirin is often used in-
stead of an anticoagulant, considering the less aggressive 
nature of isolated distal DVT, but this method lacks firm 
evidence [23]. After the decision to anticoagulate, the choice 
of drugs and duration may follow the treatment strategies 
for proximal DVT of the lower extremities.
Treatment of pulmonary embolism
Treatment of hemodynamically unstable pulmonary embolism:  
Patients with life-threatening PE may require additional 
treatment beyond anticoagulation, including systemic 
thrombolysis, catheter-directed therapy, and embolectomy. 
A meta-analysis showed that the use of thrombolytics was 
associated with lower all-cause mortality. The reduction in 
mortality seems to be mainly accounted for by studies includ-
ing hemodynamically unstable patients [24]. Anticoagulation 
should be started when the patient becomes stable, without 
bleeding complications after thrombolysis.
Treatment of hemodynamically stable pulmonary embolism: 
Anticoagulation is the mainstay of treatment for patients 
with confirmed PE and should be given to all patients with 
suspicion of the disease in the absence of active bleeding, 
even before a diagnosis of PE is confirmed. The anti-
coagulation of patients with PE has changed considerably 
in recent years, since DOACs were introduced. DOACs have 
shown similar efficacy and safety to those of conventional 
anticoagulants in patients with acute PE in several large 
randomized clinical trials [8-11, 25]. The risk reduction for 
recurrent VTE with different DOACs has not been directly 
compared, but based on indirect comparisons, it appears 
to be similar among all DOACs.
The recommended treatment duration for PE is usually 
6 months but may range from 3 months in patients with 
a transient risk factor to indefinite in patients with ongoing 
major risk factors (e.g., cancer, recurrent unprovoked PE).
Treatment of subsegmental pulmonary embolism:  Subsegmental 
pulmonary embolism (SSPE) is diagnosed when PE does 
not involve the proximal pulmonary arteries. The decision 
on whether to treat asymptomatic SSPE patients remains 
to be an issue; a recommendation cannot be supported by 
high-quality randomized clinical trials, because computed 
tomographic (CT) angiography may result in a false-positive 
diagnosis (especially in cases with a single subsegmental in-
volvement in 1 image and normal D-dimer), and the data 
with respect to whether SSPE could be progressive or re-
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current without anticoagulation are still controversial [26, 
27]. Patients with SSPE should undergo bilateral Doppler 
ultrasonography of the lower extremities [28], and high-risk 
DVT sites, such as upper extremities with indwelling central 
venous catheters. Patients who are asymptomatic, have no 
co-existing DVT or high-risk features [29] of recurrent or 
progressive VTE (immobilization, active cancer, unprovoked 
VTE), and are at high risk of bleeding may undergo surveil-
lance with serial screening for DVT of the lower leg without 
anticoagulation. However, if patients are symptomatic, have 
co-existing DVT and/or high-risk features, and have no 
bleeding risk, anticoagulation should be suggested rather 
than surveillance only. When deciding on anticoagulation, 
the choice of drugs and duration may follow the treatment 
strategies recommended for PE in larger pulmonary arteries.
Incidental pulmonary embolism:  Incidental PE is frequently 
reported on enhanced chest CT scans. Although the embolic 
load in incidental PE is usually lower than that in sympto-
matic PE, anticoagulation should be initiated if it involves 
a location proximal to the subsegmental vasculature [30]. 
In cases of incidental SSPE, the data are conflicting, as dis-
cussed in Section 4.2.3. Some investigators suggest ob-
servation without the use of anticoagulants in this group.
Treatment of cancer-associated venous thromboembolism
CAT is a common complication of cancer, associated with 
high morbidity and mortality rates. Once CAT is confirmed, 
physicians should consider anticoagulant therapy regardless 
of whether or not a patient has thrombosis-related symptoms. 
However, limited life expectancy with advanced cancer, high 
bleeding risks especially in severe thrombocytopenia, or 
thrombotic symptoms that cannot be expected to improve 
are factors that prevent the initiation of anticoagulation.
In accordance with major clinical trials comparing LMWH 
with VKA [14, 31], LMWH was previously the standard 
treatment for CAT, owing to its efficacy against thrombosis 
recurrence and improved safety profile compared to VKA. 
Recently, DOACs have emerged as potential alternative 
therapies to LMWH owing to their convenient route of ad-
ministration and predictable pharmacokinetics. However, 
evidence for their use in CAT is inconclusive, as only a 
small fraction of the study populations in these trials had 
CAT [32]. Recently, a Korean phase IV study with rivarox-
aban [6] and 2 phase III trials comparing DOACs to LMWH 
in patients with CAT [13, 33] reported comparable efficacies 
with slightly increased bleeding risk for DOACs. Based on 
the results of these 2 randomized controlled trials, the latest 
guidelines included rivaroxaban and edoxaban as options 
for VTE treatment [34]. Careful choice of treatment candi-
dates and proper anticoagulant strategies are critical for the 
treatment of CAT [34, 35]. For anticoagulation in patients 
with CAT and thrombocytopenia, see the subsection 
‘Anticoagulation in thrombocytopenia’.
Treatment of venous thrombosis of other sites
Treatment of superficial venous thrombophlebitis: Although 
superficial thrombophlebitis is considered benign and 
self-limiting, there is increasing recognition that a significant 
proportion of those presenting with this disorder will have 
concomitant DVT or PE or are at a significant risk of develop-
ing VTE [36]. The treatment of superficial thrombophlebitis 
remains controversial. However, therapeutic strategies must 
include symptomatic relief, limitation of thrombosis ex-
tension, and reduction in PE risk. A randomized controlled 
trial showed that anticoagulation with UFH, LMWH, and 
VKA were superior to compression therapy alone in reducing 
superficial thrombophlebitis extension [37, 38]. The 
SURPRISE study suggested the usability of an oral anti-
coagulant (rivaroxaban) in patients with superficial thrombo-
phlebitis [39]. Current guidelines recommend treating super-
ficial thrombophlebitis of at least 5 cm in length with prophy-
lactic doses of fondaparinux or LMWH for 45 days, but 
guidelines state that for patients with less extensive super-
ficial thrombophlebitis, anticoagulant treatment is not neces-
sary [16].
Treatment of catheter-related venous thrombosis: Thrombotic 
complications associated with the use of catheters are com-
mon in patients with cancer, leading to patient distress, cathe-
ter dysfunction, and infection. There are no large, pro-
spective, randomized trials of treatments for catheter-related 
thrombosis [40]. Symptomatic catheter-related thrombosis 
is treated with anticoagulation alone, generally without cath-
eter removal. The optimal duration of anticoagulation for 
catheter-related thrombosis has not been investigated in clin-
ical trials. The American College of Chest Physicians (ACCP) 
guidelines recommend anticoagulation for 3 months if the 
catheter has been removed and for as long as the catheter 
is in place if ＞3 months [16]. Recently, DOACs can re-
portedly be used in cancer patients with catheter-related 
thrombosis [41, 42]. Multiple reviews of strategies for pre-
venting catheter-related thrombosis are available [43, 44].
Treatment of splanchnic vein thrombosis: Splanchnic vein 
thrombosis (SVT) is the most common form of unusual site 
thrombosis, comprising approximately 4% of all thrombotic 
events. SVT encompasses thrombosis in the portal, mesen-
teric, hepatic, and splenic veins [45]. Doppler ultra-
sonography is the first-line choice for the diagnosis of portal 
and hepatic vein thrombosis, and CT angiography is the 
diagnostic modality of choice for detecting mesenteric vein 
thrombosis [46]. The most common acquired risk factors 
for SVT are abdominal cancers (especially hepatobiliary, gas-
trointestinal, and pancreatic), liver cirrhosis, and myeloproli-
ferative neoplasms (MPNs). Thus, in non-cirrhotic, non-ma-
lignant SVT patients, screening for MPNs (i.e., JAK2 muta-
tion analysis) and paroxysmal nocturnal hemoglobinuria is 
recommended, even in patients with normal complete blood 
cell counts [47]. No high-quality randomized controlled trial 
has yet been reported, but several guidelines or reviews 
have suggested the management of SVTs [48-51]. Acute, 
symptomatic, extensive SVTs, and patients planning to un-
dergo liver transplantation are recommended to undergo 
anticoagulation over surveillance. Esophageal or fundic vari-
ces, especially in cirrhotic patients, are not a contraindication 
for anticoagulation, but adequate prophylactic treatment 
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Fig. 2. Pregnancy-adapted YEARS 
algorithm for suspected acute 
pulmonary embolism in pregnant 
patients. a)If a woman has clinical 
sign of DVT, check compression 
ultrasonography of the symptomatic 
leg and initiate anticoagulant if 
DVT is confirmed. b)Initiate ant-
icoagulant if chest CTPA indicates 
PE.
Abbreviations: CTPA, computed 
pulmonary angiography; DVT, deep
vein thrombosis; PE, pulmonary 
embolism.
(with -blockers, endoscopic ligation, etc.) should precede 
anticoagulation. To date, there is no data on DOACs for 
the treatment of SVTs. UFH, LMWH, and heparin transition 
to VKA are recommended for SVTs. At least 3 months of 
anticoagulation is recommended for all SVT patients; patients 
with transient risk factors (surgery, infections) may dis-
continue treatment after 3 months of anticoagulation, but 
patients with cirrhosis, active cancer, MPNs, and other 
thrombophilic conditions should undergo extended anti-
coagulation while weighing its risks and benefits. In every 
circumstance, gastrointestinal bleeding should be monitored 
before or during anticoagulation and should be properly 
controlled.
Venous thromboembolism associated with pregnancy
Although its absolute risk is low (0.6–1.2 of every 1,000 
deliveries) [52], VTE is an important issue in pregnant wom-
en, as it is one of the most common causes of maternal 
morbidity and mortality [53]. Among VTE cases, PE is a 
particularly important cause of maternal death. For pregnant 
women with suspected PE, undergoing computed tomo-
graphic pulmonary angiography (CTPA) or ven-
tilation-perfusion scan is often inevitable because of the lim-
ited diagnostic specificity and sensitivity of D-dimer. A re-
cently published pregnancy-adapted YEARS algorithm for 
the diagnosis of suspected PE can be used to rule out PE 
safely; in a prospective study, 32–65% of patients avoided 
unnecessary CTPA scanning, with the highest efficiency during 
the 1st trimester (Fig. 2) [54].
Pregnant women with acute VTE should receive 
anticoagulation. VKA is contraindicated due to the risk of 
fetal malformations. The safety of DOACs is not supported 
by the literature, and concerns have been raised regarding 
fetal safety in some studies [55]. LMWH is preferred over 
UFH in terms of convenience.
In times of delivery, a scheduled delivery is suggested 
if a therapeutic dose of LMWH is administered, based on 
a 1.9-fold increased risk of bleeding in spontaneous labor 
compared to planned delivery [56]. In contrast, spontaneous 
labor is allowed if a woman receives only a prophylactic 
dose of LMWH [53]. For breastfeeding women, UFH, 
LMWH, and VKA are considered safe anticoagulants, while 
DOACs are not yet recommended because of insufficient 
data [53].
Venous thromboembolism in children
Cause and risk factors of venous thromboembolism in children: 
Venous thrombosis in children is rare and is mostly associated 
with multifactorial medical conditions [57]. The incidence 
of symptomatic VTE in neonates is 0.51 per 10,000 [58], 
and in children, 0.07 to 0.14 per 10,000 [59, 60]. In the 
Canadian registry, 96% of DVT/PE cases were associated 
with medical conditions, including cancer, congenital heart 
disease, or trauma. The single most important and frequent 
risk factor for VTE is a central venous catheter (CVC) [61], 
found in 33–48% of VTE cases in children [59, 61]. The 
rate of CVC as a risk factor is as high as 94% in neonates 
[59]. In contrast, inherited thrombophilia was reported in 
only 8.8% of the cohort [61]. Factor V Leiden and pro-
thrombin gene mutations are frequent in Caucasian patients 
but not in those of Asian ethnicity. The incidence of protein 
C deficiency is 0.2–0.5% in the general population but 2–5% 
in VTE individuals [62-65]. Measurement of protein S is 
very challenging, and the incidence of deficiency is thought 
to be as low as 0.9% [66]. The prevalence of hereditary 
antithrombin III deficiency is estimated to be 0.03–0.8% 
[67].
The utility of diagnostic tests for inherited thrombophilia in 
children:  A panel of tests for thrombophilia should include 
factor V Leiden mutations; prothrombin 20210 mutations; 
deficiencies of antithrombin, protein C, and protein S; homo-
cysteine levels; factor VIII levels; lipoprotein levels; and 
detection of antiphospholipid antibodies [68]. The devel-
opmental stage of the hemostatic system in children, physio-
logically lower levels of coagulant and anticoagulant proteins, 
and other confounding factors, such as concomitant use of 
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drug, infection, or inflammation, should be addressed 
[68-70]. Generally, the tests for thrombophilia do not change 
decisions about the initiation and duration of acute manage-
ment, except for specific patients with purpura fulminans 
complicating severe protein C or S deficiency or cases with 
VKA-induced skin necrosis [71-73].
Testing in patients with unprovoked, spontaneous, or re-
current thrombotic events, which are rare in children and 
adolescents, may help to identify inherited thrombophilia 
and guide management [57, 68]. Up to half of VTE events 
at unusual sites, such as the cerebral or splanchnic veins, 
and stroke are associated with inherited thrombophilia, and 
the patients are candidates for testing [74, 75]. Therefore, 
testing after the 1st episode of CVC-related VTE without 
a strong family history (a first-degree relative with VTE 
in patients under 40 years old) is not generally recommended 
[76].
Treatment of venous thromboembolism in children: Treatment 
recommendations for pediatric VTE are based on studies 
from adult populations, as scarce evidence exists in children 
[77]. Treatment options for VTE in children include anti-
coagulation, thrombolysis, surgery, and observation [78]. 
Potential benefits must be weighed against risks in premature 
neonates and critically ill children who are at high risk 
of bleeding [79]. Options for acute anticoagulation include 
UFH or LMWH, but LMWH is more frequently used because 
of the ease of dosing and the low need for monitoring [79]. 
After an acute period of anticoagulation with UFH or LMWH, 
patients may continue to receive LMWH, or a transition 
may be made to VKA [77]. When starting a patient on VKA, 
UFH or LMWH, admnistration should be continued until 
the international normalized ratio (INR) reaches the ther-
apeutic range and remains there for 2 days. In most cases, 
this process takes 5 to 7 days [77]. Anticoagulation with 
LMWH or VKA, rather than no anticoagulation, is recom-
mended in children with symptomatic DVT or PE [77, 78]. 
It is suggested to use anticoagulation for ≤3 months in 
children with provoked DVT or PE and for 6 to 12 months 
in unprovoked DVT or PE [77]. Patients with recurrent 
thrombosis and antiphospholipid antibody syndrome often 
require indefinite anticoagulation [72]. Therapeutic UFH in 
children is titrated to achieve an activated partial thrombo-
plastin time range (aPTT) of 1.5 to 2.5 times the upper limit 
of normal [77]. For neonates and children receiving either 
once- or twice-daily therapeutic LMWH, the drug needs 
to be monitored with a target anti-Xa activity range of 0.5 
to 1.0 unit/mL in a sample taken 4 to 6 h after subcutaneous 
injection [77]. For children receiving VKA, the drug needs 
to be monitored to a target INR of 2.5 (range, 2.0–3.0), 
except for those with prosthetic cardiac valves, who are 
recommended to adhere to the adult guidelines [77]. 
Symptomatic CVC-related thrombi can be treated without 
removal if the catheter is functioning. A nonfunctioning 
or unnecessary catheter should be removed after 3 to 5 days 
of therapeutic anticoagulation. The total recommended anti-
coagulant duration is between 6 weeks and 3 months [77]. 
Thrombolytic therapy should be used only for life- or 
limb-threatening thrombosis [78]. Thrombectomy followed 
by anticoagulation or IVC filter insertion is not recom-
mended except in specific, limited circumstances; rather, 
anticoagulation alone should be used in children with symp-
tomatic DVT or PE [78]. DOACs have potential benefits 
for children, including oral administration, and possibly no 
need for monitoring. Many clinical trials of DOACs are un-
derway, but the routine use of DOACs is not yet recom-
mended in children [80].
TREATMENT AFTER AN INITIAL FAILURE OF 
ANTICOAGULATION
To date, there has been no randomized trial or prospective 
cohort study to guide treatment after an initial failure of 
anticoagulation. Inadequate anticoagulation (inadequate dos-
age, poor compliance, discontinuation for an anticipated pro-
cedure, malabsorption) is the most common cause of re-
current VTE during therapy. However, recurrent VTE should 
be confirmed by radiologic testing and should be examined 
for other etiologies, such as malignancy, May-Thurner syn-
drome, inherited thrombotic disorders, or antiphospholipid 
antibody syndrome. Treatment options for initial failure in-
clude increasing the dose or administration frequency of 
the anticoagulants or alternate agents. In patients receiving 
VKA (with an INR of 2.0 to 3.0) or an adequate dose of 
a DOAC, the guideline recommends changing to LMWH 
at least temporarily [16]. In patients receiving LMWH, the 
guidelines recommend increasing the LMWH dose by 25 
to 33% [16]. The efficacy of DOACs in this population has 
not yet been studied.
REVERSAL OF ANTICOAGULATION
In VTE patients, anticoagulation reversal is required in 
times of bleeding, invasive procedures or surgery, and 
over-anticoagulation. Reversal should be decided according 
to the situation of an individual patient, balancing the bene-
fits and risks [81]. Table 2 summarizes the key pharmacoki-
netic features and the approved or potential antidotes for 
anticoagulants.
Oral or intravenous vitamin K can be used for severe 
prolongation (＞8) or moderate prolongation (5–8) of the 
INR with bleeding or significant risk of bleeding [82]. Fresh 
frozen plasma is commonly used because of its low cost 
and ease of use. Protamine sulfate is an approved drug for 
the reversal of UFH. It should be slowly infused with doses 
of 1 mg per 80–100 U of UFH for neutralization [83]. Although 
LMWH has a stronger inhibitory effect on Xa than on throm-
bin, protamine sulfate can be considered as an antidote for 
LMWH at a dose of 1 mg per 100 U of LMWH [83].
Novel antidotes for DOACs are currently available in some 
countries or under clinical trials. Idarucizumab is an en-
gineered antibody fragment with a structure similar to that 
of thrombin; it binds to dabigatran. It showed good reversal 
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Table 2. Characteristics of common anticoagulants and its approved or potential antidotes.
Anticoagulants Metabolism and excretion Plasma half-life Antidotes
UFH Rapid endothelial internalization
Slow renal clearance
40–90 minutes Protamine sulfate 
LMWH Renal excretion 4 hours Protamine sulfate (ciraparantaga))
VKA Hepatic metabolism 40 hours Oral or IV Vitamin K
Fresh frozen plasma
Dabigatran 80% renal, 20% hepatic 13 hours Idarucizumab (ciraparantaga))
Apixaban 27% renal, 73% hepatic 12 hours Andexanet alfa (ciraparantaga))
(andexanet alfa, ciraparantaga))
Andexanet alfa (ciraparantaga))
Edoxaban 50% renal, 50% hepatic 10–14 hours
Rivaroxaban 35% renal, 65% hepatic 5–9 hours
a)Under investigation.
Abbreviations: IV, intravenous; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; VKA, vitamin K antagonist.
efficacy in a pivotal phase III trial [84] and was approved 
by the United States (U.S.) Food and Drug Administration 
(FDA) in 2015. Andexanet alfa is a modified, recombinant 
human factor Xa protein that binds to factor Xa inhibitors 
and LMWH but is catalytically inactive. It received U.S. 
FDA accelerated approval for patients taking rivaroxaban 
or apixaban who require reversal. Recently, full data from 
a multicenter, open-label study were published; among pa-
tients taking factor Xa inhibitors suffering from major bleed-
ing, andexanet alfa resulted in 82% excellent or good hemo-
static efficacy at 12 hours with remarkably reduced anti-Xa 
activity [85]. Ciraparantag is another broad-spectrum re-
versal agent under investigation. It is a synthetic small mole-
cule that binds to and inhibits Xa inhibitors, UFH, LMWH, 
and fondaparinux [86].
MONITORING AND DRUG-DRUG 
INTERACTION OF DOACS
DOACs can be used at fixed doses without testing levels 
in most patients, and this feature is obviously an advantage 
of DOACs compared to VKA. However, emerging data sug-
gest that measuring the DOAC concentration would be bene-
ficial in certain critical circumstances [87]. If done properly, 
monitoring of DOACs can guide decision-making regarding 
the pursuit of invasive procedures or the use of costly reversal 
agents. In conventional laboratory testing, thrombin time 
and aPTT can reflect the activity of dabigatran [88] but 
are imperfect and often result in false-negative findings, 
particularly for aPTT [89]. Prothrombin time and/or aPTT 
are often prolonged after the use of Xa inhibitors, but the 
degree of prolongation does not correlate with DOAC levels, 
and the results vary according to the reagents used [90]. 
Chromogenic assays for anti-Xa are reliable and relatively 
cost-effective, with proper calibration [91]. Liquid chroma-
tography/tandem mass spectrometry is the gold standard 
method for monitoring DOACs, but it is not practical for 
clinical laboratory use [92]. Future development of 
DOAC-specific tests with good test reliability, faster turn-
around time, and affordable cost are necessary to monitor 
DOACs more accurately and provide clinical benefits.
Drug-drug interactions involving DOACs can arise either 
via pharmacokinetic or pharmacodynamic mechanisms [93]. 
DOACs are pharmacokinetically dependent on varying de-
grees of cytochrome CYP3A and P-glycoprotein. Therefore, 
concomitant administration of commonly used drugs can 
alter DOAC activity. The pharmacodynamics of DOACs can 
be augmented by some classes of drugs, such as antiplatelet 
compounds, nonsteroidal anti-inflammatory drugs, and se-
lective serotonin or noradrenaline reuptake inhibitors [93]. 
The use of other drugs should be carefully checked, and 
the prescription should be adjusted by a professional pharma-
cist while considering potential drug-drug interactions, espe-
cially in the elderly with polypharmacy or cancer patients 
undergoing active treatment.
CONCLUSION
The treatment of VTE has changed significantly in recent 
years, after the insurance coverage of DOACs began. The 
emergence of anticoagulants with a lower risk of bleeding 
and easy use has led to the replacement of warfarin and 
heparin by DOACs in most situations where anticoagulation 
is indicated.
In the future, 2 factors need to be considered to improve 
the Korean VTE treatment guidelines. First, studies examin-
ing whether lower doses of anticoagulants can maintain their 
therapeutic effects while reducing bleeding side effects are 
a worldwide issue. These studies are necessary, particularly 
for Korean VTE patients with a high risk of bleeding. Second, 
the diagnosis of asymptomatic incidental VTE is increasing 
due to a changing medical environment, and updated treat-
ment guidelines are urgently required. The current recom-
mendations are based not only on insufficient evidence, but 
also mostly on Western data. Therefore, recommendations 
need to be amended based on Korean data in the future.
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